Pomalidomide Patent Expiration
Pomalidomide is used for treating multiple myeloma in patients who have already received other prior therapies. It was first introduced by Bristol Myers Squibb Co
Pomalidomide Patents
Given below is the list of patents protecting Pomalidomide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pomalyst | US10555939 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | May 19, 2030 | Bristol |
| Pomalyst |
US10555939 (Pediatric) | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Nov 19, 2030 | Bristol |
| Pomalyst | US5635517 | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Jul 24, 2016
(Expired) | Bristol |
| Pomalyst | US5653517 | Process and system for determination of friction/slip characteristics of road vehicle tires |
Jul 24, 2016
(Expired) | Bristol |
| Pomalyst | US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US6316471 | Isoindolines, method of use, and pharmaceutical compositions |
Aug 10, 2016
(Expired) | Bristol |
| Pomalyst | US6476052 | Isoindolines, method of use, and pharmaceutical compositions |
Jul 24, 2016
(Expired) | Bristol |
| Pomalyst | US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US8158653 | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline |
Aug 10, 2016
(Expired) | Bristol |
| Pomalyst | US8198262 | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione | Jun 17, 2025 | Bristol |
| Pomalyst |
US8198262 (Pediatric) | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione | Dec 17, 2025 | Bristol |
| Pomalyst | US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US8673939 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May 15, 2023
(Expired) | Bristol |
| Pomalyst |
US8673939 (Pediatric) | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov 15, 2023
(Expired) | Bristol |
| Pomalyst | US8735428 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May 15, 2023
(Expired) | Bristol |
| Pomalyst |
US8735428 (Pediatric) | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov 15, 2023
(Expired) | Bristol |
| Pomalyst | US8828427 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Jun 21, 2031 | Bristol |
| Pomalyst |
US8828427 (Pediatric) | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Dec 21, 2031 | Bristol |
| Pomalyst | US9993467 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | May 19, 2030 | Bristol |
| Pomalyst |
US9993467 (Pediatric) | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Nov 19, 2030 | Bristol |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Pomalidomide Generics
Several generic applications have been filed for Pomalidomide. The first generic version for Pomalidomide was by Breckenridge Pharmaceutical Inc and was approved on Oct 30, 2020. And the latest generic version is by Apotex Inc and was approved on Jun 11, 2024.
Given below is the list of companies who have filed for Pomalidomide generic.
1. MYLAN
Mylan Pharmaceuticals Inc has filed for 4 different strengths of generic version for Pomalidomide. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | capsule | Discontinued | ORAL | N/A | Jan 26, 2022 |
| 1MG | capsule | Discontinued | ORAL | N/A | Jan 26, 2022 |
| 2MG | capsule | Discontinued | ORAL | N/A | Jan 26, 2022 |
| 3MG | capsule | Discontinued | ORAL | N/A | Jan 26, 2022 |
2. TEVA PHARMS USA
Teva Pharmaceuticals Usa Inc has filed for 4 different strengths of generic version for Pomalidomide. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | capsule | Discontinued | ORAL | N/A | May 4, 2022 |
| 4MG | capsule | Discontinued | ORAL | N/A | May 4, 2022 |
| 3MG | capsule | Discontinued | ORAL | N/A | May 4, 2022 |
| 2MG | capsule | Discontinued | ORAL | N/A | May 4, 2022 |
3. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 4 different strengths of generic version for Pomalidomide. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 4MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 3MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 2MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
4. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 4 different strengths of generic version for Pomalidomide. Given below are the details of the strengths of this generic introduced by Breckenridge.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 2MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 3MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 4MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
5. APOTEX
Apotex Inc has filed for 4 different strengths of generic version for Pomalidomide. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | capsule | Prescription | ORAL | AB | Jun 11, 2024 |
| 2MG | capsule | Prescription | ORAL | AB | Jun 11, 2024 |
| 3MG | capsule | Prescription | ORAL | AB | Jun 11, 2024 |
| 1MG | capsule | Prescription | ORAL | AB | Jun 11, 2024 |